NFL Biosciences SA (EPA:ALNFL)

France flag France · Delayed Price · Currency is EUR
1.110
+0.028 (2.59%)
Feb 20, 2026, 5:23 PM CET
Market Cap14.07M -19.8%
Revenue (ttm)164.00 +645.5%
Net Income-3.15M
EPSn/a
Shares Out12.67M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume59,879
Average Volume153,729
Open1.100
Previous Close1.082
Day's Range1.056 - 1.116
52-Week Range0.851 - 1.860
Beta1.32
RSI39.24
Earnings DateApr 15, 2026

About NFL Biosciences

NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company’s pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding of the mechanism of action of NFL-101, its proprietary botanical drug candidate for smoking cessation. NFL Biosciences SA was incorporated in 2006 and... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 5
Stock Exchange Euronext Paris
Ticker Symbol ALNFL
Full Company Profile

Financial Performance

In 2024, NFL Biosciences's revenue was 46, a decrease of -99.98% compared to the previous year's 200,011. Losses were -2.08 million, -44.44% less than in 2023.

Financial Statements